Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Prostate Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
31 drugs · 100 active trials
7 drugs · 60 active trials
24 drugs · 406 active trials
Outside the funnel: Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 6 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lutetium (177lu) Vipivotide Tetraxetan | Phase 3 | Phase 3 | 20 | 14 | 2 | 29 | 0 | — | — | 2016-12 |
| Carboplatin | Phase 3 | Phase 3 | 17 | 8 | 3 | 43 | 0 | — | — | 1998-04 |
| Nivolumab | Phase 3 | Phase 3 | 14 | 3 | 2 | 35 | 0 | — | — | 2006-08 |
| Atezolizumab | Phase 3 | Phase 3 | 9 | 4 | 2 | 12 | 0 | — | — | Sep 5, 2017 |
| Cabozantinib | Phase 3 | Phase 3 | 8 | 3 | 4 | 21 | 0 | — | — | 2011-04 |
| Ipilimumab | Phase 3 | Phase 3 | 6 | 2 | 2 | 28 | 0 | — | — | May 13, 2003 |
| Hormone Therapy | Phase 3 | Phase 3 | 4 | 1 | 5 | 9 | 0 | — | — | 2003-06 |
| Histrelin | Phase 3 | Phase 3 | 4 | 2 | 4 | 6 | 0 | — | — | 2000-04 |
| Etoposide | Phase 3 | Phase 3 | 3 | 1 | 1 | 12 | 0 | — | — | 1997-12 |
| Cisplatin | Phase 3 | Phase 3 | 3 | 2 | 1 | 9 | 0 | — | — | 1998-09 |
| Paclitaxel | Phase 3 | Phase 3 | 2 | 1 | 2 | 28 | 0 | — | — | 1997-04 |
| Bevacizumab | Phase 3 | Phase 3 | 2 | 2 | 2 | 18 | 0 | — | — | 2001-06 |
| Abemaciclib | Phase 3 | Phase 3 | 2 | 1 | 1 | 8 | 0 | — | — | Nov 26, 2018 |
| Buserelin | Phase 3 | Phase 3 | 2 | 0 | 5 | 6 | 0 | — | — | Feb 8, 1995 |
| Ipatasertib | Phase 3 | Phase 3 | 2 | 0 | 1 | 5 | 0 | — | — | Jan 11, 2012 |
| Celecoxib | Phase 3 | Phase 3 | 1 | 0 | 2 | 10 | 0 | — | — | 2001-05 |
| Tamoxifen | Phase 3 | Phase 3 | 1 | 0 | 1 | 4 | 0 | — | — | 2002-11 |
| Estramustine | Phase 3 | Phase 3 | 0 | 0 | 7 | 40 | 0 | — | — | 1995-03 |
| Mitoxantrone | Phase 3 | Phase 3 | 0 | 0 | 6 | 24 | 0 | — | — | 1997-03 |
| Doxorubicin | Phase 3 | Phase 3 | 0 | 0 | 4 | 20 | 0 | — | — | 1995-03 |
| Everolimus | Phase 3 | Phase 3 | 0 | 0 | 1 | 14 | 0 | — | — | 2004-03 |
| Lenalidomide | Phase 3 | Phase 3 | 0 | 0 | 1 | 10 | 0 | — | — | 2005-04 |
| Thalidomide | Phase 3 | Phase 3 | 0 | 0 | 1 | 8 | 0 | — | — | 1999-12 |
| Gemcitabine | Phase 3 | Phase 3 | 0 | 0 | 1 | 7 | 0 | — | — | 2000-03 |
| Cyproterone Acetate | Phase 3 | Phase 3 | 0 | 0 | 5 | 6 | 0 | — | — | 1987-05 |
| Sirolimus | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2006-08 |
| Vinblastine | Phase 3 | Phase 3 | 0 | 0 | 3 | 4 | 0 | — | — | 1996-08 |
| Galeterone | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | 2009-10 |
| Toremifene | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2001-04 |
| Diethylstilbestrol | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2002-12 |
| Ibandronic Acid | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2003-04 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.